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ABSTRACT: Background: The Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) cohort study of
the Canadian Consortium on Neurodegeneration in Aging (CCNA) is a national initiative to catalyze research on dementia, set up to
support the research agendas of CCNA teams. This cross-country longitudinal cohort of 2310 deeply phenotyped subjects with various
forms of dementia and mild memory loss or concerns, along with cognitively intact elderly subjects, will test hypotheses generated by
these teams. Methods: The COMPASS-ND protocol, initial grant proposal for funding, fifth semi-annual CCNA Progress Report
submitted to the Canadian Institutes of Health Research December 2017, and other documents supplemented by modifications made and
lessons learned after implementation were used by the authors to create the description of the study provided here. Results: The CCNA
COMPASS-ND cohort includes participants from across Canada with various cognitive conditions associated with or at risk of
neurodegenerative diseases. They will undergo a wide range of experimental, clinical, imaging, and genetic investigation to specifically
address the causes, diagnosis, treatment, and prevention of these conditions in the aging population. Data derived from clinical and
cognitive assessments, biospecimens, brain imaging, genetics, and brain donations will be used to test hypotheses generated by CCNA
research teams and other Canadian researchers. The study is the most comprehensive and ambitious Canadian study of dementia. Initial
data posting occurred in 2018, with the full cohort to be accrued by 2020. Conclusion:Availability of data from the COMPASS-ND study
will provide a major stimulus for dementia research in Canada in the coming years.
RÉSUMÉ : Évaluation complète d’une étude de cohorte canadienne portant sur la démence et la neuro-dégénérescence. Contexte : L’évaluation
globale de la neuro-dégénérescence et de la démence (COMPASS-ND), étude de cohorte du Consortium canadien en neuro-dégénérescence associée au
vieillissement (CCNV), représente une initiative nationale visant à promouvoir la recherche portant sur la démence et à soutenir les programmes de recherche
des équipes du CCNV. Totalisant 2310 sujets recrutés partout au pays, cette cohorte longitudinale regroupe des individus fortement « phénotypés » qui
présentent diverses formes de démence et de pertes de mémoire légères. En plus de sujets âgés dont les fonctions cognitives sont intactes, ces 2310 sujets ont
permis de valider les hypothèses formulées par les équipes du CCNV.Méthodes : Nous avons utilisé de nombreux documents pour décrire cette étude : le
protocole de la COMPASS-ND ; la demande initiale de subvention ; le cinquième rapport d’étape semi-annuel du CCNV soumis aux Instituts de recherche
From the Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada (HC); Lady Davis Institute, Montreal, Quebec, Canada (HC, VW, RP); Department
of Medicine, University of Toronto, Toronto, Ontario, Canada (S Black, MM); Sunnybrook Research Institute, Toronto, Ontario, Canada (S Black, MM, MCT); Department of Geriatric
Medicine, Western University, London, Ontario, Canada (MB); Lawson Health Research Institute, London, Ontario, Canada (MB, JF, JL, S Best); Department of Medicine, University of
British Columbia, Vancouver, British Columbia, Canada (HHF, G-YRH); Department of Neurosciences, University of California, San Diego, California, USA (HHF); Department of
Psychiatry, McGill University, Montreal, Quebec, Canada (SG, JP); Department of Medicine, University of Calgary, Calgary, Alberta, Canada (DBH); The Hotchkiss Brain Institute,
Calgary, Alberta, Canada (DBH, EES); Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada (KM); Toronto Rehabilitation Institute, Toronto,
Ontario, Canada (KM); Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada (KR, MA); Department of Physiology and Pharmacology, Western University,
London, Ontario, Canada (JR); Robarts Research, London, Ontario, Canada (JR); Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada
(MCT); Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada (G-YRH); Department of Medicine, University of Alberta, Edmonton, Alberta, Canada (RC);
Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (RC); Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (EES); Department of
Psychiatry, Western University, London, Ontario, Canada (JF); McConnell Brain Imaging Centre, McGill University, Montreal, Quebec, Canada (AE); McGill Centre for Integrative
Neuroscience, Montreal, Quebec, Canada (S Das, ZM); Department of Psychology, Concordia University, Montreal, Quebec, Canada (NP); Department of Medicine, McGill University,
Montreal, Quebec, Canada (EM); Department of Psychology, University of Alberta, Edmonton, Alberta, Canada (RD); Department of Radiology, Laval University, Quebec City, Quebec,
Canada (S Duchesne); Centre de recherche de l’Institut universitaire en santé mentale de Québec, Université Laval, Québec City, Québec, Canada (S Duchesne); Department of Pathology
and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada (IM); McGill Center for Studies in Aging, Douglas Hospital, McGill University,
Montreal, Quebec, Canada (SG).
RECEIVED OCTOBER 16, 2018. FINAL REVISIONS SUBMITTED FEBRUARY 22, 2019. DATE OF ACCEPTANCE FEBRUARY 25, 2019.
Correspondence to: Howard Chertkow, Kimel Family Building, Baycrest Health Sciences, 3560 Bathurst Street, Toronto, Ontario, M6A 2E1, Canada. Email: Howard.
chertkow@mcgill.ca
ORIGINAL ARTICLE COPYRIGHT © 2019 THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC.
THIS IS AN OPEN ACCESS ARTICLE, DISTRIBUTED UNDER THE TERMS OF THE CREATIVE COMMONS ATTRIBUTION LICENCE (HTTP://CREATIVECOMMONS.ORG/LICENSES/BY/4.0/), WHICH PERMITS UNRESTRICTED
RE-USE, DISTRIBUTION, AND REPRODUCTION IN ANY MEDIUM, PROVIDED THE ORIGINAL WORK IS PROPERLY CITED.
THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES 499
https://www.cambridge.org/core/terms. https://doi.org/10.1017/cjn.2019.27
Downloaded from https://www.cambridge.org/core. IP address: 75.80.147.55, on 05 Jun 2020 at 02:16:01, subject to the Cambridge Core terms of use, available at
en santé du Canada (IRSC) en décembre 2017 ; ainsi que d’autres documents produits à la suite de modifications consécutives à la mise en œuvre de ce
projet. Résultats : L’étude de cohorte COMPASS-ND du CCNV inclut des participants de partout au Canada dont les divers états cognitifs sont associés à
des maladies neurodégénératives ou au risque d’en souffrir. Ils feront l’objet d’un large éventail d’examens expérimentaux, cliniques, génétiques et
d’imagerie afin d’aborder de manière spécifique les causes, le diagnostic, le traitement et la prévention de ces états cognitifs chez les personnes âgées. Les
données obtenues à la suite d’évaluations cliniques et cognitives, ainsi que celles issues d’échantillons biologiques, d’imagerie cérébrale, de tests génétiques
et de dons de cerveaux, seront utilisées pour tester les hypothèses générées par les équipes de recherche du CCNV et d’autres chercheurs canadiens. Cette
étude constitue donc à ce jour l’étude canadienne la plus complète et la plus ambitieuse au sujet de la démence. La présentation des données initiales ayant eu
lieu en 2018, la cohorte devrait atteindre sa taille maximale d’ici à 2020. Conclusion : La disponibilité des données de l’étude COMPASS-ND stimulera
considérablement la recherche sur la démence au Canada au cours des prochaines années.
Keywords: Cohort study, Dementia, Frontotemporal dementia, Biomarkers, Diagnosis, Alzheimers
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BACKGROUND
The Canadian Institutes of Health Research (CIHR) estab-
lished the Canadian Consortium on Neurodegeneration in Aging
(CCNA) as the major national vehicle to coordinate and strength-
en Canadian research on Alzheimer’s Disease (AD) and other
neurodegenerative diseases (NDDs). CCNA was intended to
foster innovative and collaborative research, and brings together
most of the established senior Canadian researchers in dementia.
Twenty teams were established with expertise spanning from
basic science to clinical areas of research. Details of CCNA are
available at www.ccna-ccnv.ca.
It quickly became evident that numerous clinical questions
remain to be answered – for instance, what are the clinical and
biomarker profiles of mixed dementia subjects compared to
other forms of dementia? Fifteen of the twenty CCNA teams
wished to test hypotheses and obtain data involving human
subjects with various forms of memory complaints or loss and
NDDs. The decision was made to create a single national study
within CCNA that would include cohorts of individuals with
various cognitive concerns and/or NDDs. Participants would be
recruited from memory, stroke, and Parkinson’s disease and
movement disorders clinics. This would allow the gathering of
complementary data from across the country. The cohort study,
a Comprehensive Assessment of Neurodegeneration and De-
mentia (COMPASS-ND) creates the infrastructure nationally
for recruiting centers and data collection, with most sites based
in academic clinical research centers in Canada. Thirty-one data
collection sites across the country have been established for
recruitment. Many of the principal investigators also serve
within the Canadian Consortium of Centres for Clinical Cogni-
tive Research (C5R), a national clinical trials network. Over 60
researchers working in a number of committees spent 2 years
designing the final protocol that will gather the information
required for answering the 106 core research questions posed by
the 15 CCNA teams.
The study will ultimately enroll 1650 individuals with differ-
ent NDDs and/or degrees of memory loss or concern, as well as a
comparison group of cognitively intact older subjects (n= 660)
being collected through separate financial support obtained from
the CIHR Big Data in Dementia grant, the Broad and deep
Analysis in Neurodegeneration (BRAIN) study. The enrolment
of COMPASS-ND is currently (May 2019) at 50% and should be
completed by 2020. In this paper, we describe the methodology
and components of the COMPASS-ND study.
METHODS
Members of the Research Executive Committee (REC) as well
as the COMPASS-ND Protocol Implementation Team collabo-
rated in the preparation of this manuscript. The submitted and
approved protocols for the COMPASS-ND study were reviewed.
The initial grant proposal and the fifth semi-annual progress
report, which was submitted to CIHR in December 2017, were
utilized. News and press items as well as policies and operating
guidelines posted on the website (www.ccna-ccnv.ca) were also
reviewed and incorporated into the Results section. Finally,
modifications made after implementation of the initial protocol
are noted where relevant.
RESULTS
1. Conceptual Framework
COMPASS-ND was designed to recruit participants with a
range of the NDDs of aging. The NDDs encountered in older
persons consist of a family of related clinical–pathological enti-
ties. AD is the most common form of NDD and contributes in
whole or in part to approximately two-thirds of dementia cases in
older adults.1 Vascular dementia accounts for up to 20% of
dementia cases, second only to AD.2 While vascular cognitive
impairment is not infrequently the result of a stroke, most
commonly, it is not preceded by a discrete cerebrovascular
event.3 Mixed dementia – cognitive impairment where multiple
brain pathologies are present – represents the most prevalent type
of cognitive impairment.4 Frontotemporal dementia (FTD)
accounts for 20% of early onset (i.e., <65 years of age) dementia
cases with symptoms beginning on average around 45–65 years
of age.5 Symptoms of FTD progress at a rapid, steady rate with
survival after diagnosis between 2 and 10 years in most.6
Dementia with Lewy Bodies accounts for about 5% of cases of
dementia.7
To date, a collaborative approach to research that spans a wide
breadth of presumably related NDD has rarely been undertaken.
COMPASS-ND was designed to include and span a wide range
of conditions. This enables comparisons to be made across
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disease states. This also enables the identification of common and
unique factors across these diseases. Furthermore, creation of
core assessment platforms that include multiple modalities will
give us a more comprehensive evaluation of brain health in each
of these disease states than is currently available. Using these
multiple modalities will provide the opportunity to identify
clinical, imaging, genetic, and other biological markers associated
with the different neurodegenerative and vascular pathologies in
the pathogenesis of adult onset dementia.
There is an urgency to be able to identify those who will
develop NDD before their functional abilities are compromised,
so that treatment may be enacted to maintain independence. It is
well established that those with mild cognitive impairment (MCI)
are at increased risk for progression to a dementia,8 but it remains
a subject for debate what proportion of patients with MCI will
eventually develop dementia and who they are.9,10 In recent
years, there has been increased interest in those who have a
complaint about their cognition but no objective impairment.
This population has been referred as having subjective cognitive
impairment (SCI). There is evidence that they are at increased
risk of developing dementia.11,12 Because of this interest in early
diagnosis and developing predictor biomarkers, it was elected to
enroll MCI (in its broadest terms) and SCI cohorts.
The primary goal of COMPASS-ND is to create a pan-
Canadian cohort that will, for the first time, integrate a wide
range of experimental, clinical, cognitive, imaging, and genetic
information and be a valuable resource for researchers. Using
current diagnostic criteria (see online Supplementary material),
our goal was to establish research cohorts that are well charac-
terized in terms of their demographics, pre-morbid history,
cognitive function, genetic profile, neural structure and pathology,
and important biomarkers and biological indices. These data will
then be made available to the research teams, allowing them
access to a more extensive dataset than is typically possible.
2. General Study Objectives
For each of the study cohorts, we are:
1. Collecting data on sociodemographic characteristics, med-
ical and social history, physical examination, and past and
current medications, as well as gait assessment and sensory
function (audition and vision), and questions related to
cognitive reserve and reproductive history.
2. Collecting neuropsychological data assessing episodic,
associative and prospective memory, attention, language,
visuoperceptual abilities, processing speed, and executive
function.
3. Carrying out collection of biosamples of blood, saliva, and
urine in all participants, and cerebrospinal fluid (CSF)
collection in at least 25% of the cohort.
4. Collecting MRI data according to Canadian Dementia
Imaging Protocol (CDIP).
5. Identifying psychosocial issues to inform the development
of programmes to support patients and families.
3. Study Design
This is a longitudinal observational cohort study that allows
embedded interventions for subgroups. The cohorts are defined by
clinical cognitive syndromes with agreed on diagnostic criteria.
A total of 1650 memory-impaired/concerned subjects, including
those with SCI/Subjective Cognitive Decline (SCD), vascular MCI
(V-MCI)/MCI, AD/Mixed dementia, Lewy Body Dementia
(LBD)/Parkinson’s disease dementia (PDD)/Parkinson’s disease
MCI (PD-MCI), and FTD/primary progressive aphasias (PPA),
along with 660 cognitively normal individuals will be enrolled into
this study from 31 centers (i.e., memory clinics affiliated with the
C5R, select Canadian stroke clinics, and select Canadian move-
ment disorders clinics). Patients will be 50–90 years of age and
recruited to ensure adequate representation of male and female
participants in each diagnostic subgroup. We will ensure that the
male/female distribution within each diagnostic group mirrors that
found in the general population. The assessment was initially
planned as a cross-sectional study, but with additional funding
from the BRAIN grant, there will be a planned follow-up evalua-
tion at 2-year-post-recruitment. The goal is to repeat the entire set
of procedures below (except genetic testing) for this second
assessment. If CCNA goes on to a Phase II renewal, further
longitudinal follow-ups will be arranged.
Study participants involved in the study will undergo com-
prehensive baseline evaluations, including clinical and neuropsy-
chological assessment, biospecimen collection, genomics, and
MRI neuroimaging. Participants may still continue to be a part of
the study if they decline to undertake certain procedures. The
minimum level of participation required for study inclusion is the
MRI scan and clinical assessment. The collected data will be
cleaned and made available to CCNA investigators as well as
others eventually through the Longitudinal Online Research and
Imaging System (LORIS) database.13
A decision was made not to conduct a strict “natural history”
study. We felt that this deeply phenotyped cohort of participants
could be targeted for small scale 6–24-month intervention studies if
willing. We have chosen to carry out primarily non-pharmacologi-
cal intervention studies of diet, exercise, and cognitive stimulation.
Specific CCNA teams are conducting these intervention studies
using COMPASS-ND subjects with MCI and SCI/SCD. The initial
COMPASS-ND assessment will function as a “pre-intervention”
evaluation, providing considerable savings in terms of cost and
participant assessment burden.
The protocol was designed to harmonize, where possible, with
ongoing Canadian and international studies of aging and demen-
tia, in particular, the Canadian Longitudinal Study of Aging
Table 1: COMPASS-ND enrolment goals
Diagnosis Minimum number
Cognitively intact elderly 660
SCI/SCD 300
MCI without vascular lesions 400
Subcortical ischemic V-MCI 200
Mild AD 150
Mild dementia of mixed etiology 200
Lewy body disease/Parkinson’s dementia 200
FTD 200
TOTAL 2310
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(CLSA),14 The Ontario Neurodegenerative Disease Research
Initiative (ONDRI), Le Consortium pour l’identification précoce
de la maladie d’Alzheimer – Québec (CIMA-Q; Consortium for
the Early Identification of AD – Québec), and the Alzheimer’s
Disease Neuroimaging Initiative (ADNI)15 to allow for cross-
study comparisons. For instance, the diet researchers designed the
dietary questionnaire to be administered,16 and it is also being
administered as part of the CLSA. One of the CCNA teams is
focused on gait and cognition, and designed similar gait measures
to gather necessary data for COMPASS-ND as well as an
associated cohort in Ontario.17
4. Participants
Leaving aside the cohort of cognitively intact older persons, a
total of 1650 subjects (see Table 1) are to be enrolled. Sample size
was determined for adequate testing of various planned hypothe-
ses, and so that sex distribution of the groups would be adequate to
enable the analysis of how sex impacts the expression of different
types of dementia. A group of cognitively intact older subjects
(n= 660) will be recruited for normative data especially on the
experimental tasks that have been developed for this study. A
subset of this group (n= 200) will undergo the full COMPASS-
ND protocol while the remainder will participate in a shortened
protocol that excludes an MRI and biosample collection.
Basic decisions around the COMPASS-ND cohort arose after
discussions with the International Scientific Advisory Board
(ISAB) of the CCNA. An important one was to focus on mixed
pathology and mixed dementias. It is anticipated that most
recruited dementia cases will have mixed pathology, co-morbidities,
and evidence of vascular disease. Exclusionary criteria are
being kept to a minimum. This was motivated by three
considerations: recent work has demonstrated extensive mixed
pathology in most older persons with dementia,18 and we wished
to enroll a more ecologically accurate dementia cohort; while we
recognized that other studies have brought forth a wealth of
information on highly selected “ready for drug trial” cases of AD
and MCI, the majority of those seen in the clinical practice are
excluded from these studies and are generally under-studied; and
research on the vascular aspects of the dementias is particularly
strong in Canada,19–21 and we felt important contributions could
be made from less restricted recruitment.
The specific inclusion and exclusion criteria for enrolling
subjects in the study are described below.
General Inclusion Criteria (All Conditions)
Subjects must meet each of the following criteria for enrol-
ment into the study:
1. Written informed consent must be obtained and documented.
2. Sufficient proficiency in English or French to undergo
assessment. Good proficiency on the Language Experience
and Proficiency Questionnaire (LEAP-Q),22 a self-assessment
measure of linguistic ability for both speaking and under-
standing of English or French, is required for inclusion into
the study.
3. Geographic accessibility (living within 1 h to the study
site) is required.
4. Must have a study partner who sees the participant weekly,
and who can participate as required in the protocol.
General Exclusion Criteria (All Conditions)
1. The presence of other significant known chronic brain
disease (e.g., moderate to severe chronic static leukoence-
phalopathy including previous traumatic injury), multiple
sclerosis, a serious developmental handicap, malignant
tumors, Huntington’s disease, and other rarer brain illnesses
2. Ongoing alcohol or drug abuse
3. Subject does not have a study partner
4. Individuals where English or French is not sufficiently
proficient
5. Total score on the Montreal Cognitive Assessment
(MoCA) < 13
Figure 1: Flow plan of the assessments in COMPASS-ND.
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6. Symptomatic stroke within the previous year
7. Unwilling or unable to undergo MRI scan
5. Assessments
The five assessment visits include extensive clinical testing
and questionnaires; auditory, visual, and gait measures; an
in-depth neuropsychological battery; physical examination; 3T
MRI scan; and blood, saliva, fecal, and urine collection for
multiple biosample measures. If the subject agrees, a lumbar
puncture is carried out at Visit 5. There will be a 12-week window
from time of consent to complete all screening and baseline
procedures. The overall assessment plan is seen in Figure 1.
(A) (Visit 1) Consent, Demographics, and Screening Clinical
Assessments (Estimated Time: 2–2.5 h)
The following study procedures are performed:
• Written informed consent prior to study procedures
• Assessment of inclusion/exclusion criteria
• Hearing and vision assessment
• Sociodemographic, physical activity, and nutrition and oral
health information
• Logical Memory 1 and 2 from Wechsler Memory Scale-
Revised23
• Clinical Dementia Rating scale24
• Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) Word List Recall25
• MoCA26 (those with SCI/SCD must have a score ≥ 25; all
participants must have a score ≥ 13)
• Lawton Brody Instrumental Activities of Daily Living scale27
• Benson Figure Recall28
• Mini-mental state examination (MMSE)29
• National Alzheimer’s Coordinating Center (NACC) Uni-
form Data Set frontotemporal lobar dementia (FTLD) Mod-
ule to delineate clinical features of PPA and behavioral
variant FTD (bvFTD)30
• Geriatric Depression scale and Generalized Anxiety Disor-
der 7-item Scale
(B) Self-Administered Questionnaires to be Completed
between Visits 1 and 2
A take home package is filled out by caregivers at home
including information on:
- Hobbies and leisure activities, tobacco and alcohol
consumption, activities of daily living, quality of life, end
of life care, social network, support, and activities
- Formal questionnaires on: adverse childhood experiences
(optional), the Neuropsychiatric Inventory,31 the Parkin-
son’s Disease Questionnaire (PDQ-39),32 and the UPDRS
version revised by the Movement Disorders Society MDS-
UPDRS, parts IB – II (LBD, PDD, PD-MCI, PD-NCI, and
FTD spectrum only)33
- FTD spectrum subjects’ caregivers will also fill out scales
on the Behavioral Inhibition Scale Interpersonal Reactivity
Self-Monitoring, along with an Apathy Inventory
In addition, there will be an at-home fecal collection for
microbiome assessment.
(C) Visit 2: Completion of Clinical and Physical Assessments
(Estimated Time: 2.5–3 h)
At visit 2, the following information is gathered and study
procedures performed by the study nurse:
- Physical measurements, health perception, fatigue, falls
history and balance assessment, walking speed at 4 and 6
m, and grip strength
- Formal vision assessment, olfaction assessment, and hear-
ing assessment
- Reported sleep features, caregiver burden and cognitive
fluctuations
- Clinical details of disease onset and progression, medical,
mental health, surgical history, and family history
- Physical and neurological examination
- Hachinski Ischemic Scale34
- Clinical diagnosis reassessment (Diagnostic criteria are
attached as online Supplemental material)
- Collection of fasting blood, saliva, urine, and buccal
swab
(D) Visit 3: Neuropsychological Assessment (Estimated Time:
3–3.5 h)
At visit 3, the following information will be gathered and
study procedures performed (also see Table 2):
- Visuoperceptual and construction ability
- Learning and memory
- Attention, working memory, and processing speed
- Executive function
- Speech and language
(E) Visit 4: MRI Scan (Estimated Time: 1 h)
At visit 4, a magnetic resonance imaging scan is performed on
a 3T magnet machine. It may be done prior to the clinical and
neuropsychological assessments but must be done prior to the
lumbar puncture.
(F) Visit 5: Lumbar Puncture (Estimated Time: 1 h)
At visit 5, a lumbar puncture is performed optionally if
consented to by the participant.
(G) Follow-Up
All cohort subjects and/or informants will be contacted via
telephone on an annual basis to ensure continued willingness to
participate and request permission to consult their treating phy-
sician to determine if there has been any diagnostic change. If
there is consent for a brain donation upon the participant’s death,
their brain will be collected according to established protocols.
All subjects will be seen in person 2 years after recruitment and
undergo the same procedures as in visits 1–4.
6. Clinical evaluation
The clinical assessment consists of demographics, past and
current medical/psychiatric conditions, past and current medica-
tions, reproductive history, childhood adversity, past and current
sleep quality/patterns, past and current pain status, nutrition,
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lifestyle factors including physical and social activity, and other
domains of interest. The clinical items were chosen to overlap as
much as possible with several large-scale provincial initiatives
(i.e., CIMA-Q35 ONDRI36).
7. Neuropsychological Evaluation
The neuropsychology test battery was designed to assess a
comprehensive range of cognitive domains and be sensitive to a
range of ability levels, ranging from older adults with relatively
intact cognitive abilities to participants with diagnosed dementia.
This cognitive test battery is independent from the cognitive
screening tests used to classify participants above (Section 5A,
Screening Visit). Neuropsychological testing will provide a char-
acterization of the participant’s cognitive profile to discriminate
dementia types and track changes with dementia progression.
Domains assessed will be broad based and include attention,
learning and memory, speech production, language, executive
function, and visuospatial function (see Table 2 below). The
Movement Disorder Society Task Force Guidelines were used to
design the battery of clinical tests for Parkinson’s disease patient
cohort. The test battery was chosen to overlap as much as possible
with several large-scale provincial initiatives (i.e., CIMA-Q35
ONDRI36) and several provincial disease-specific studies (FTD
in British Columbia37 and Parkinson’s disease in Alberta38). The
battery requires between 2 and 3 h to administer.
8. Biosamples
Dementia biomarkers may be measured in blood,39 CSF,40
and saliva.41 They can help us to better understand the mechan-
isms and effects of neurodegeneration and provide potential
Table 2: Neuropsychological battery
Test battery
Domain Test Description Time (min)
Premorbid IQ WAIS-III Vocabulary* Expressive vocabulary 10
Visuoperceptual and construction ability Object Decision Test –BORB Object perception 5
Judgment of Line Orientation (split half) Visual perception 10
BVMT Copy Visuoconstruction 3
Learning and memory RAVLT* Word-list learning 5–8
BVMT* Figure learning 10–15
CCNA/CIMA-Q Face–Name Matching Associative recall 10–15
Digit Symbol – Incidental Recall Incidental associative recall 5
Envelope Test* Prospective memory 5
Attention and working memory and
processing speed
WAIS-III Digit Span forward and backward Attention span and working memory 5–10
WAIS-III Digit Symbol-Coding Psychomotor processing speed 5
CCNA Simple and Choice Reaction Time Reaction time 10
Executive function D–KEFS Phonemic Fluency* Phonemic (letter) fluency 5
Reitan Trail Making Test (A & B)* Attention switching 5–10
D–KEFS Color Word Interference Interference resolution; switching 7–12
CCNA/CIMA-Q Sentence Completion
Test*
Inhibition (verbal) 10
NACC Social Norms Questionnaire Knowledge of appropriate social mores 5
NACC Social Behavior Observer Checklist Social behavior and self-awareness 5
Speech and language D–KEFS Semantic Fluency* Semantic (category) fluency 3
Cookie Theft Picture Description Free speech 2
NACC Word Reading Test Reading of regular and irregular words 2–3
NACC Semantic Word–Picture Matching
Test
Word recognition and comprehension 5
NACC Semantic Associates Test Semantic memory 5
NACC Northwestern Anagram Test Grammatical knowledge 10
NACC Sentence Repetition Test Oral repetition 1
NACC Noun and Verb Naming Subtests Naming of objects and actions 6
NACC Sentence Reading Test Reading 1
BORB=Birmingham Object Recognition Battery; BVMT=Brief Visuospatial Memory Test; D–KEFS=Delis–Kaplan Executive Function System;
NACC=National Alzheimer’s Coordinating Center; RAVLT=Rey Auditory Verbal Learning Test; WAIS=Weschler Adult Intelligence Scale.
*Tests monitored 100% of the time. All testing sessions are audio-recorded.
THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
504
https://www.cambridge.org/core/terms. https://doi.org/10.1017/cjn.2019.27
Downloaded from https://www.cambridge.org/core. IP address: 75.80.147.55, on 05 Jun 2020 at 02:16:01, subject to the Cambridge Core terms of use, available at
diagnostic markers to aid in earlier diagnosis of these diseases.
Blood, urine, and saliva will be collected on all participants, who
will also be asked if they are willing to undergo a lumbar
puncture to provide CSF samples (based on our review of similar
observational studies that included the option of a lumbar punc-
ture, this is a conservative estimate).42
A total of 53.4 mL of blood will be collected via venipuncture
in 10 tubes. A total of 4 mL of saliva will be collected by passive
drool in one tube. A total of 40 mL of CSF will be collected via
lumbar puncture. The samples will be aliquoted into 500-μL V
bottom, screw-top tubes (Matrix Tubes, Thermo Fisher Scientific,
Carlsbad, CA) and stored in a –80°C fridge until they can be
transported via cryoshipper to the Canadian Biosample Reposi-
tory (CBSR) in Edmonton for more permanent storage.
Core biomarkers will be assessed at the clinical laboratory of
the Jewish General Hospital in Montreal (Dr. E. MacNamara,
director). The samples are being collected, handled, stored, and
shipped according to rigorously established standard operating
procedures.
A set of core established biomarkers will be assessed for all
participants including general measures of health, measures of
sex-related hormones, inflammation, lipid metabolism, and oxi-
dative stress. Further experimental measures will be assessed on
sub-samples of participants based on the needs of the researchers.
See Table 3 and Figures 2 and 3 for the Blood and Fluids
Processing Plan.
9. MRI Scanning
A workshop of Canadian imaging experts led by Dr. Simon
Duchesne developed the CDIP, which will be used in
COMPASS-ND.43 The particular sequences used are all stan-
dardized across MRI machines throughout the country and
include 3D T1, PD/T2, FLAIR, gradient echo, resting state fMRI,
and Diffusion Tensor Imaging (DTI). The 3 tesla (3T) MRI scans
planned as part of COMPASS-ND will allow comparison with
ADNI data. CDIP will also be used in a growing number of other
Canadian brain study cohorts, including ONDRI, CIMA-Q, and
the Canadian Alliance for Healthy Hearts and Minds.44 By using
exactly the same sequences in these different studies, the potential
to combine and compare across them becomes possible.
The following analyses of MRI images will be carried out on
each subject when possible:
1. Core Tissue Classification and Volumetrics. Structural
MRI will be performed using acquisition protocols that
have already been standardized across vendor platforms
and are compatible with the current ADNI protocols, the
VCI Harmonization criteria, and guidelines for detecting
amyloid-related imaging abnormalities. The core proto-
col allows tissue compartment classification, including a
sophisticated subtype analysis of vascular lesions, clas-
sified as lacunes, and as lesions in the periventricular or
deep nuclei/white matter (not connected to the ventri-
cles). This pipeline has been developed over the last
decade and combines automatic and user-assisted man-
ual steps.
2. Automated Hippocampal Segmentation. This will be
contracted out to “True Positive,” a spin-off McGill
company that has developed real-time volumetrics for
clinical trials. The data will be loaded into LORIS.
3. DTI. Preprocessing will initially be based on standard
approaches using FMRIB Software Library that have prov-
en effective in measuring significantly preserved white
matter integrity in elderly bilinguals versus monolinguals
(mean age= 70.5 years., SD= 3 years.) based on significant
differences in fractional anisotropy and radial diffusivity.
4. Resting State fMRI. Preprocessed resting-state data sets
will be provided within CCNA for each subject utilizing
automated pipelines.
5. Visual Review for Vascular Lesions. This will be carried
out according to the Standards for Reporting Vascular
Changes on Neuroimaging (Strive) protocol.45 Visual
classification of infarcts, lacunes, white matter hyperinten-
sity burden by the Fazekas scale, 46 microbleeds, and
superficial siderosis will be carried out by MRI Core Labs
at the University of Calgary and Sunnybrook Hospital
(University of Toronto) by qualified MR readers. Infarcts
will be classified by size, location, and vascular territory,
Table 3: List of blood and CSF biomarkers in planned analysis
Blood
Electrolytes (Na, K, Cl, and bicarbonate) Androstenedione
Creatinine Luteinizing hormone
Urea Follicle-stimulating hormone
Insulin level Dehydroepiandrosterone sulfate
Glucose Estrone sulphate
Liver function (AST, ALT, ALP, and
bilirubin)
Testosterone (total)
B12 Dihydrotestosterone
Homocysteine Estrone
C-reactive protein Estradiol
Insulin-like growth factor 1 Prolactin
Tumor necrosis factor-alpha Cortisol
Interleukin 6 Sex hormone-binding globulin
Total cholesterol Thyroid stimulating hormone
Triglycerides Calcium
High density lipoproteins Albumin
Low density lipoproteins 25-OH vitamin D level
ApoA-1 Ferritin
ApoB Cystatin c
Alpha-1-antitrypsin Brain derived neurotrophic factor (serum
and RNA)
Biliverdin Vascular endothelial growth factor (serum
and RNA)
Adrenocorticotropic hormone
CSF
Amyloid-beta 1–42
Total tau
Phosphorylated tau
Alpha synuclein
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while microbleeds will be classified by location and by
pattern according to Boston criteria for cerebral amyloid
angiopathy.
10. Genetics
We will carry out extensive genotyping of all subjects within
COMPASS-ND.47 All samples will be genotyped at the Mt. Sinai
Clinical Genomics Centre (CGC)/University of Toronto using the
Affymetrix UK Biobank Axiom array chip suitable for genetic
association analysis for all NDDs. This chip will provide a cost-
effective common, cross-disease platform for the discovery of:
(a) all known mutations (∼1000) in genes known to cause AD;
(b) ∼20,000 key tagging SNPs for all genome-wide significant
loci published in human GWAS for PD, FTLD, ALS, AD, and
stroke together with the top ∼1000 SNPs just below genome-
wide significance; (c) ∼349,000 coding sequence variants with a
frequency of >1% in the human genome. It will provide 820,967
markers overall. All data will be archived in LORIS to allow us to
evaluate the common and rare genetic susceptibility components
in our subjects, giving a deep genotypic phenotyping to match the
depth of study of clinical and imaging data. Uniquely, we will be
able for the first time to test for rare monogenic and complex
polygenic susceptibility across the full range of patients with
neurodegenerative disorders. Familial cases with high opportu-
nity for discovery of novel genes and novel variants will undergo
whole-exome sequencing.
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11. Microbiome Assessment
Emergent research is linking the microbiome to a myriad of
clinical conditions, including inflammation, several gastrointes-
tinal disorders, asthma, obesity, Type 2 diabetes, as well as brain
disorders such as anxiety, depression, autism, and stress
response.48,49 Factors released by the gut microbiome have been
shown recently to directly modify function of microglia, the
brain’s immune cells, providing a mechanistic link between the
periphery and brain inflammation. Gut microbiota makes or
affects several neurotransmitters, and sectioning the vagus nerve
decreases the occurrence of Parkinson’s disease.49,50 This
suggests that any large data set acquisition should include a
microbiome analysis. Although there are several “smoking guns”
that the microbiota may impact on Alzheimer’s,49,51–53 there have
not been defined cohort studies to directly examine this. There is
considerable expertise in Canada under Dr. Brett Finlay and his
University of British Columbia team to carry out these analyses.
We are collecting fecal and oral samples for bacterial DNA
studies from our COMPASS-ND cohort.53 A family member at
home collects the fecal samples after the first visit. The oral
scraping is taken at Visit 2. Both collections will use the Norgen
Biotek Swab Collection and Preservation System. All samples
are then shipped to the CBSR in Edmonton and from there to
the laboratory of Dr. Brett Finlay at UBC for microbiome
processing.
This cutting edge assessment will give an insight into the
inflammatory state of NDD subjects, which will complement the
measures of inflammation in blood, and CSF being collected. This
initiative would directly address this, with the added benefit of
having all the accompanying clinical data, making it an extremely
novel and important aspect to further understanding AD.54
12. Brain Donation and Brain Banking
For many NDDs, a definitive diagnosis can only be made
through analysis of brain tissue generally acquired at autopsy.
Tissue pathology is still the “gold standard” for diagnosis and is
an important tool to examine epigenetic and proteomic aspects of
NDDs.55,56 COMPASS-ND will work closely with the Canadian
ADNI Brain Donation and Neuropathology Network (CABIN)
led by Dr. Ian Mackenzie. Funds from CABIN will collect ADNI
brains and COMPASS-ND brains. We are setting up a national
brain donation system, standardized dementia neuropathology
protocols, and creating a set of national brain tissue banks for
dementia studies. This will be a national resource that will allow
correlations between pathology and longitudinal clinical, neuro-
psychological, and imaging data. Assessment of brain tissue post-
mortem will provide definitive diagnoses for the various types of
NDDs that enrolled in COMPASS-ND. Results derived from the
anonymized brain tissue samples will be attached to the other data
related to that COMPASS-ND subject. This will allow clinical
pathological-genetic-imaging correlations to be studied. Brain
tissue from well-characterized cases will be made available for
Canadian researchers.
13. Data Storage and Management
COMPASS-ND data being collected on participants are being
uploaded and stored in the LORIS database. The LORIS data
management system is based at McGill University and is directed
by Dr. Alan Evans.13 It is a modular and extensible web-based
data management system that integrates all aspects of a multi-
center study: from heterogeneous data acquisition (imaging,
clinical, behavior, and genetics) to storage, processing, and
ultimately dissemination. It is storing data that have been pro-
cessed to remove any direct identifiers of an individual study
participant. Study subjects are being assigned a unique anon-
ymized study identification number that will be used to store their
data. LORIS CCNA data will be accessible to all CCNA mem-
bers, and ultimately to the entire Canadian and international
research community through the GAAIN Portal system.57 The
subjects’ confidentiality will be maintained. Information about
study subjects will be made publicly available to the extent
permitted by the applicable laws and regulations. In CCNA
publications, only group data will be reported.
14. Partnerships
It should be noted that while the questionnaires, examinations,
psychometric testing, and biomarkers were planned to answer
specific hypotheses, we also took into consideration a need to
synergize with other partners in Canada who were to be potential
sources of subjects. A partnership has been established with an
overlapping natural history cohort in Ontario (ONDRI) and a
cohort in Quebec (CIMA-Q). Many of the data collection sites for
COMPASS-ND are also involved in those studies. It is hoped that
several hundred of their research subjects may become subse-
quent subjects in COMPASS-ND. To this end, about one-third of
the data to be collected was designed to overlap in a comple-
mentary fashion with their procedures and questions, with the
goal of avoiding unnecessary subject burden and cost. Contracts
and data sharing arrangements have been undertaken. Further
overlap in psychometric testing was geared toward comparisons
with the CLSA14 which is a population-based study of aging in
over 50,000 individuals who will be followed for 20 years. The
study includes a psychometric evaluation as well as biospecimen
collection but currently no brain imaging.
15. Normative Comparison Group
The original plan of COMPASS-ND did not include funding
for a separate cognitively intact elderly control group. Additional
funding through the BRAIN grant will allow us to establish a
control group of cognitively intact older individuals as previously
described. These individuals are being accrued under direction of
CCNA team leaders Drs. Natalie Philips and Roger Dixon. In
addition to providing the necessary control data for comparisons
with the patient participant groups, the COMPASS-ND will
provide normative neuropsychological data on the COMPASS-
ND cognitive battery to be used by memory clinics across
Canada.
16. Intervention Studies within COMPASS-ND
We are leveraging the considerable opportunity offered by the
deep phenotyping within COMPASS-ND to launch three inter-
ventional studies with largely non-pharmacological approaches.
The economy of this approach is that the subject is assessed
initially for entry into COMPASS-ND, then undergoes the
intervention, and then is restudied and reassessed. The initial
COMPASS-ND assessment thus becomes the baseline for the
study, with considerable saving of costs. The downside of this
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approach is that these subjects (particularly if they are in the
active intervention arm and particularly if the intervention proves
successful) are then lost as part of a “natural history of progres-
sion” study. It is our view, however, that the benefits of devel-
oping new interventions for the NDDs outweigh this loss and is
the most appropriate approach to follow.
The intervention studies consist of the SYNERGIC (Synchro-
nizing Exercise Remedies in Gait and Cognition) study, a
6-month study of intensive exercise plus or without Vitamin
D, carried out in MCI individuals (n= 160); the ENGAGE study
(Exploring Novel Group Activities for Geriatric Enrichment) – a
6-month study of cognitive stimulation interventions (or placebo)
carried out by Team 10 under Drs. Sylvie Belleville and Nicole
Anderson in 200 SCI individuals in Toronto and Montreal; and
the LEAD study (Lifestyle Exercise and Dementia), a 1-year
study of dietary and exercise interventions carried out in MCI and
SCI individuals.
17. Administration and Governance of COMPASS-ND
The CCNA is administered as a grant from CIHR. The REC
directs the scientific management of CCNA. On the REC, two
members (Dr. Howard H. Feldman and Dr. Michael Borrie)
represent the COMPASS-ND study. The REC has bi-weekly
teleconferences and has several in-person meetings a year. As
head of the Clinical Platform of CCNA, Dr. Michael Borrie plays
a critical role in the implementation of COMPASS-ND and is
supported by Sarah Best, Dr. Jennifer Fogarty, Cynthia Di
Prospero, and Nimi Bassi. The Protocol Implementation Team
of COMPASS-ND meets every week to deal with day-to-day
operational issues. The reimbursement of site costs and payment
for participant accrual are managed by the central administration
of CCNA.
18. Data Access and Publication
The guiding principle of COMPASS-ND is to maximize
access to and use of the valuable data being collected, and to
catalyze the Canadian dementia research community. The clinical,
neuropsychological, imaging, biomarker, and genomic data
from each clinical site or laboratory within CCNA will be
managed and uploaded centrally to the LORIS database. A
Publications and Data Access Committee (PDAC) was estab-
lished as a sub-committee of the CCNA REC. PDAC policy does
not in itself restrict analysis of CCNA data, which might be with a
view to publication, pilot testing, or education. Access to and
analyses of COMPASS-ND study data by CCNA investigators
will be granted automatically upon request of access. However,
as part of their team and group agendas, many CCNA investi-
gators (the teams, platforms, and REC) have already submitted a
list of “Protected planned projects and publications,” which
constitutes a writing plan for CCNA for the first 12 months after
the full COMPASS-ND cross-sectional data have been collected,
uploaded into LORIS, and locked. This 12-month period will
allow the designated teams to write the planned papers. All
CCNA investigators are expected to honor the priority of the
list of “Protected” topics, since the teams and platforms that
designed the COMPASS-ND study did so as a means to address
specific hypotheses. After the quarantine period, any CCNA
investigator can undertake/publish research on any question that
has not been addressed yet. To do so, the CCNA investigator
must submit a summary of the project/publication proposed to the
PDAC. The PDAC will verify that the project has not already
been submitted by a CCNA team of platform. After the quaran-
tine period, non-CCNA investigators may be granted access to
CCNA acquired data upon submission of a project outline
supporting their data access request. Ultimately, all COM-
PASS-ND data will become part of the GAAIN portal open
access system.
A Biological Samples Access Committee was also set up to
establish policy and procedures for the disposition and allocation
of the biological samples that are obtained from participants in
CCNA studies. It will also review applications from CCNA and
non-CCNA researchers for studies that propose to use CCNA
biological specimens, with specified criteria. An accounting of
the biological specimens available to the research community
through CCNA will be maintained in the CCNA
19. The Ethical and Legal Aspects of COMPASS-ND
Paramount in COMPASS-ND is subject confidentiality. We
have worked closely with the CCNA Ethical Legal and Social
Implications of the research (ELSI) Committee under the direction
of Dr. Serge Gauthier to deal with ethical issues raised by such a
multi-centre study. COMPASS-ND will be conducted in compli-
ance with the protocol, International Conference on Harmonization
Good Clinical Practice and the applicable regulatory requirements.
Any medically significant incidental findings (as judged by the site
research physician) will be communicated to the patient’s personal
physician, who will decide on appropriate subsequent communi-
cation of the finding to the participant along with possible
treatment options. COMPASS-ND also provides an opportunity
to assess to what degree knowledge of biomarkers (CSF, imaging,
and blood and genetics) would alter the diagnosis and management
of physicians. A CCNA Clinical Diagnosis Committee is currently
exploring how to carry out ethical relaying of biomarker informa-
tion back to treating physicians in order to track the impact of this
information on diagnosis and treatment.
20. Involvement in International Collaborations
COMPASS-ND will be an important achievement for the
Canadian dementia research community. However, it is clear that
our cohorts do not supply sufficient sample sizes to answer many
questions about gene/environment interactions. We will partner
with international groups to pool deeply phenotyped subjects.
Internationally, similar (and similarly sized) cohorts are being
collected in other countries. A Memorandum of Understanding
with the UK Dementia Platform has already been brought into
effect, and other international agreements are being pursued. It is
hoped that CCNA will also be positioned to negotiate Canada’s
participation in international dementia prevention studies in the
future.
CONCLUSION
In the COMPASS-ND study, a national dementia cohort of
2310 “deeply phenotyped” affected individuals, and cognitively
intact controls, is being established that will catalyze research
across both basic and clinical research fields in dementia in
Canada. This will be unique in focusing on disease heterogeneity,
mixed dementias, and comparing and contrasting different
dementia types in great detail.
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Novel intervention studies of diet, exercise, and cognitive
stimulation have been leveraged off of these deeply characterized
COMPASS-ND subjects with mild memory loss, and these are
ongoing. Possible new therapeutic approaches may result. Moving
forward, we anticipate further developing initiative that can
prevent progression from MCI to dementia and ensure the rele-
vance of dementia research to people living now at high risk of
developing dementia within a short period.
We believe COMPASS-ND will allow CCNA to lead the way
in bringing cooperation and collegiality to dementia research and
researchers. COMPASS-ND represents a uniquely Canadian
partnership with scientists and clinicians working together and
pooling resources to obtain information out of the reach of
individual researchers. Working together, we can make even
faster progress toward our common goal of dealing with the
challenge of NDDs.
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